RecruitingNCT06419699

CPAx: Responsiveness and Minimal Clinically Important Difference

Responsiveness and the Minimal Clinically Important Difference of the Chelsea Critical Care Physical Assessment Tool (CPAx) in Critically Ill, Mechanically Ventilated Adults


Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

120 participants

Start Date

May 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Intensive care unit (ICU) acquired weakness is a common complication associated with long-term physical impairments in survivors of a critical illness. The Chelsea Critical Care Physical Assessment tool (CPAx) is a valid and reliable instrument for physical function and activity in critically ill patients at risk for muscle weakness. However, its ability to measure change over time (responsiveness) and the minimal clinically important difference (MCID) have not yet been rigorously investigated. This multi-centre, mixed-methods, longitudinal cohort study therefore aims to establish responsiveness and the MCID of the CPAx in the target population from ICU baseline to ICU and hospital discharge. The study uses routine data from standard physiotherapy sessions like mobility, function and activity with no additional burden for critically ill adults. The investigators expect the CPAx to be responsive allowing its use as a primary outcome in future effectiveness trials for the treatment of ICU-acquired weakness using the newly established MCID for sample size calculation. A high quality, rigorously tested measurement tool for physical function and activity in the ICU should benefit researchers, clinicians and patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years
  • Mechanical ventilation ≥ 72 hours
  • Expected to remain for ≥ 48 hours in the ICU
  • Physiotherapy referral

Exclusion Criteria7

  • Not expected to survive to hospital discharge (imminent to death)
  • Second or subsequent ICU admission for this hospital stay
  • Transfer from external ICU (with an ICU stay of \>72 hours)
  • Primary neurological admission diagnosis (i.e., of the central nervous system including stroke, intracerebral haemorrhage, traumatic brain injury)
  • Known pregnancy
  • Living in a care facility pre-admission (severe pre-existing mental or physical disability)
  • Local regulations (i.e. Switzerland: refusal of general consent)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(3)

Monash Health

Clayton, Australia

Alfred Health

Melbourne, Australia

Inselspital

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06419699


Related Trials